Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 12/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127906 | 0.89 | KLKB1 (0.47) | — | |
| SCHEMBL5121673 | 0.87 | KLKB1 (0.46) | — | |
| SCHEMBL5115924 | 0.87 | PDPK1 (0.50) | — | |
| SCHEMBL5125121 | 0.85 | KLKB1 (0.48) | — | |
| SCHEMBL5116179 | 0.84 | KLKB1 (0.59) | CHRM3LMNAMMP13AURKASMN1; SMN2 | |
| SCHEMBL5121861 | 0.80 | KLKB1 (0.49) | LMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5123897 | 0.79 | EPHX2 (0.47) | — | |
| SCHEMBL5118979 | 0.79 | KLKB1 (0.48) | — | |
| SCHEMBL5128253 | 0.76 | CHRM3 (0.52) | CHRM3ALDH1A1 | |
| SCHEMBL5116718 | 0.76 | TDP1 (0.67) | LMNAMEN1KMT2AMAPK1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7459452-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-12-02 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-7232819-B2 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA P. ANGELETTI S.P.A. (IT) | 2007-06-19 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DI FRANCESCO MARIA E | 2007-04-12 | — | — | US | disclosed |
| EP-1441734-B1 | DIHYDROXYPYRIMIDINE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2007-02-28 | — | — | EP | disclosed |
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075356-A1 | Dihydroxypyrimidine carboxamide inhibitors of hiv integrase | DUT, DPYD, TYMP | CHRM3 3470/4885CHRM1 2787/4885LMNA 4057/4885 |
| US-20070083045-A1 | Dihydroxypyrimidine carboxamide inhibitors of HIV integrase | DUT, DPYD, TYMP | CHRM3 3300/4885CHRM1 2833/4885LMNA 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.